STOCK TITAN

Notable Labs, Ltd. Ordinary Shares - $NTBL STOCK NEWS

Welcome to our dedicated page for Notable Labs, Ltd. Ordinary Shares news (Ticker: $NTBL), a resource for investors and traders seeking the latest updates and insights on Notable Labs, Ltd. Ordinary Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Notable Labs, Ltd. Ordinary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Notable Labs, Ltd. Ordinary Shares's position in the market.

Rhea-AI Summary
Notable Labs, (NTBL) reported financial results for 2023, highlighted by successful clinical data from their Precision Medicine Platform. The company plans to advance its clinical program for lead product candidate, volasertib, in 2024. Notable Labs aims to leverage its platform to predict patient responses, enhance enrollment, and increase the likelihood of success. Financially, the company ended 2023 with $11.8 million in cash, with a current balance of $8.2 million as of April 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
-
Rhea-AI Summary
Notable Labs, presents the design for a Phase 2 trial with volasertib and decitabine in patients with relapsed/refractory AML at AACR 2024. The company aims to predict responders using their PPMP and develop a companion diagnostic test.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.48%
Tags
-
Rhea-AI Summary
Notable Labs, (NTBL) presented data on innovations in using cryopreserved samples in their Precision Oncology Platform at AACR 2024. The study showed cryopreserved samples can predict treatment response in acute myeloid leukemia with high accuracy, opening new avenues for treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.15%
Tags
none
Rhea-AI Summary
Notable Labs, Ltd. (NTBL) announced the presentation of two posters at AACR 2024 related to their Predictive Precision Medicine Platform (PPMP) for cancer therapies. They plan to initiate a Phase 2 program for volasertib in Q2 2024. The posters focus on clinical response prediction and ex vivo tests for acute myeloid leukemia patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
conferences
-
Rhea-AI Summary
Notable Labs, Ltd. (Nasdaq: NTBL) announces the advancement of its volasertib Phase 2 program utilizing Predictive Precision Medicine Platform (PPMP) to enrich the study population for clinical responders in relapsed/refractory acute myelogenous leukemia (r/r AML). PPMP's accurate predictions allow for the elimination of non-responders, reducing risk, time, and cost of drug development. Clinical milestones include IND filing in Q1 2024, program initiation in Q2 2024, dose optimization data in Q4 2024, and enrollment of the first PPMP-selected patient in Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
-
Rhea-AI Summary
Notable Labs, Ltd. (Nasdaq: NTBL) and CicloMed, LLC announced initial safety and efficacy data of fosciclopirox and the performance of PPMP from the Phase 2a trial in adult patients with relapsed/refractory acute myeloid leukemia. Fosciclopirox, a patented prodrug, is being developed for the treatment of bladder cancer and AML. PPMP accurately predicted patient responses, further validating its potential in drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.55%
Tags
none
Rhea-AI Summary
Notable Labs, Ltd. (Nasdaq: NTBL) has donated $60,000 to the Myelodysplastic Syndromes Foundation, Inc. during the MDS Foundation 2023 Satellite Symposium at the 65th ASH Annual Meeting in San Diego. The donation reflects the company's commitment to developing better treatments for MDS patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
none
-
Rhea-AI Summary
Notable Labs (NTBL) Donates $60,000 to the Myelodysplastic Syndrome Foundation, Inc. at the 65th American Society of Hematology Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
none
-
Rhea-AI Summary
Notable Labs, Ltd. (NTBL) CEO, Thomas Bock, to participate in fireside chat at JMP Securities Hematology and Oncology Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
conferences
Rhea-AI Summary
NTBL - Notable Labs, Ltd. Announces Q3 2023 Financial Results and Merger with VBL Therapeutics - Notable Labs, Ltd. (Nasdaq: NTBL) released its Q3 2023 financial results and announced the completion of its merger with VBL Therapeutics. The company's focus is on developing predictive precision medicines for cancer patients, with a lead program in the development of Volasertib for the treatment of acute myeloid leukemia (AML). Notable Labs, Ltd. had $14.3 million in cash and cash equivalents as of October 31, 2023, and anticipates the release of safety and efficacy data from the Phase 2a trial for Fosciclopirox before year-end 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
Notable Labs, Ltd. Ordinary Shares

Nasdaq:NTBL

NTBL Rankings

NTBL Stock Data

9.65M
170.19k
29.07%
3.35%
0.24%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
FOSTER CITY

About NTBL

vascular biogenics ltd. is a biotechnology company located in 6yonatan netanyahu street, yehud, center district, israel.